Improving the prediction of response to therapy in autism

Neurotherapeutics

Volumn 7, Issue 3, 2010, Pages 232-240

  Bent, Stephen ^a,b   Hendren, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alternative therapy; Autism; Biomarker; Complementary; Randomized controlled trials

Indexed keywords

ARIPIPRAZOLE; BIOLOGICAL MARKER; CITALOPRAM; FLUOXETINE; GLUTATHIONE; HYDROCORTISONE; ICOSANOID; INTERLEUKIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MECOBALAMIN; MEMANTINE; OMEGA 3 FATTY ACID; OXYGEN; PLACEBO; RAPAMYCIN; RISPERIDONE; TUMOR NECROSIS FACTOR ALPHA;

APPETITE; ARTICLE; AUTISM; BEHAVIOR THERAPY; BODY WEIGHT; DIZZINESS; DROWSINESS; DRUG EFFICACY; EXCITOTOXICITY; FATIGUE; FATTY ACID METABOLISM; GENE EXPRESSION; HUMAN; HYPERBARIC OXYGEN; HYPERSALIVATION; IMMUNOREACTIVITY; INFLAMMATION; MITOCHONDRIAL TOXICITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEDATION; SIDE EFFECT; TREATMENT RESPONSE; TREMOR; ALTERNATIVE MEDICINE; AUTISTIC DISORDER; METABOLISM; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AUTISTIC DISORDER; BIOLOGICAL MARKERS; COMPLEMENTARY THERAPIES; HUMANS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954902987     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.05.011     Document Type: Article

References (58)

1. Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 2009, 58:1-20. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention (CDC)Centers for Disease Control and Prevention (CDC).
2. Educating Children with Autism 2001, National Academy Press, Washington, DC.
3. Ospina M.B., Krebs Seida J., Clark B., et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PloS One 2008, 3:e3755.
4. McCracken J.T., McGough J., Shah B., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321.
5. Shea S., Turgay A., Carroll A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641.
6. Marcus R.N., Owen R., Kamen L., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48:1110-1119.
7. Owen R., Sikich L., Marcus R.N., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
8. King B.H., Hollander E., Sikich L., et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 2009, 66:583-590.
9. ACTN Trial: Study of fluoxetine in autism (SOFIA) Accessed April 21, 2009. http://www.autismspeaks.org/science/programs/ctn/index.php%23fluoxetine_study.
10. Harrington J.W., Rosen L., Garnecho A., Patrick P.A. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. J Dev Behav Pediatr 2006, 27(2 Suppl):S156-S161.
11. Heuer L., Ashwood P., Schauer J., et al. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res 2008, 1:275-283.
12. Enstrom AM, Onore CE, Van de Water JA, Ashwood P. Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun xxxx;24:64-71.
13. Enstrom A.M., Lit L., Onore C.E., et al. Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain, behavior, and immunity 2009, 23:124-133.
14. Enstrom A.M., Van de Water J.A., Ashwood P. Autoimmunity in autism. Curr Opin Investig Drugs 2009, 10:463-473.
15. Ashwood P., Wills S., Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006, 80:1-15.
16. Chez M.G., Dowling T., Patel P.B., Khanna P., Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007, 36:361-365.
17. Pardo C.A., Vargas D.L., Zimmerman A.W. Immunity, neuroglia and neuroinflammation in autism. International review of psychiatry (Abingdon, England) 2005, 17:485-495.
18. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005, 57:67-81.
19. Zimmerman A.W., Jyonouchi H., Comi A.M., et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 2005, 33:195-201.
20. Ashwood P., Wakefield A.J. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol 2006, 173:126-134.
21. Chauhan A., Chauhan V., Brown W.T., Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - the antioxidant proteins. Life Sci 2004, 75:2539-2549.
22. James S.J., Cutler P., Melnyk S., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004, 80:1611-1617.
23. Yorbik O., Sayal A., Akay C., Akbiyik D.I., Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 2002, 67:341-343.
24. Mostafa G.A., El-Hadidi E.S., Hewedi D.H., Abdou M.M. Oxidative stress in Egyptian children with autism: relation to autoimmunity. J Neuroimmunol 2010, 219:114-118.
25. James S.J., Rose S., Melnyk S., et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. Faseb J 2009, 23:2374-2383.
26. Bell J.G., Miller D., Macdonald D.J., et al. The fatty acid composition of erythrocyte and plasma polar lipids in children with autism, developmental delay or typically developing controls and the effect of fish oil intake. Br J Nutr 2010, 103:1160-1167.
27. Bell J.G., MacKinlay E.E., Dick J.R., MacDonald D.J., Boyle R.M., Glen A.C. Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids 2004, 71:201-204.
28. Meguid N.A., Atta H.M., Gouda A.S., Khalil R.O. Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem 2008, 41:1044-1048.
29. Vancassel S., Durand G., Barthelemy C., et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 2001, 65:1-7.
30. Bu B., Ashwood P., Harvey D., King I.B., Water J.Vd, Jin L.W. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot Essent Fatty Acids 2006, 74:215-221.
31. Zecavati N., Spence S.J. Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep 2009, 9:129-136.
32. Oliveira G., Diogo L., Grazina M., et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. Dev Med Child Neurol 2005, 47:185-189.
33. Weissman J.R., Kelley R.I., Bauman M.L., et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PloS One 2008, 3:e3815.
34. Aldred S., Moore K.M., Fitzgerald M., Waring R.H. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 2003, 33:93-97.
35. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol 2007, 27:317-318.
36. Fatemi S.H., Halt A.R., Stary J.M., Kanodia R., Schulz S.C., Realmuto G.R. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002, 52:805-810.
37. Polleux F., Lauder J.M. Toward a developmental neurobiology of autism. BMC Complement Altern Med 2004, 10:303-317.
38. Bertoglio K., James J.S., Deprey L., Brule N., Hendren R.L. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. BMC Complement Altern Med 2010, 16:1-6.
39. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
40. Alizadeh A.A., Staudt L.M. Genomic-scale gene expression profiling of normal and malignant immune cells. Curr Opin Immunol 2000, 12:219-225.
41. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344:539-548.
42. Staudt L.M. Gene expression physiology and pathophysiology of the immune system. Trends Immunol 2001, 22:35-40.
43. Simons J.W. Genomic medicines for oncology: early lessons. J Med Assoc Ga. Winter-Spring 2003, 92:35-38.
44. Chin K.V., Alabanza L., Fujii K., et al. Application of expression genomics for predicting treatment response in cancer. Ann N Y Acad Sci 2005, 1058:186-195.
45. Carroll W.L., Bhojwani D., Min D.J., Moskowitz N., Raetz E.A. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 2006, 46:570-578.
46. Green V.A., Pituch K.A., Itchon J., Choi A., O'Reilly M., Sigafoos J. Internet survey of treatments used by parents of children with autism. Res Dev Disabil 2006, 27:70-84.
47. Amminger G.P., Berger G.E., Schafer M.R., Klier C., Friedrich M.H., Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007, 61:551-553.
48. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002, 21:495-505.
49. Young G., Conquer J. Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 2005, 45:1-28.
50. Rossignol D.A., Rossignol L.W. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses 2006, 67:216-228.
51. Rossignol D.A. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses 2007, 68:1208-1227.
52. Rossignol D.A., Rossignol L.W., Smith S., et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr 2009, 9:21.
53. Granpeesheh D., Tarbox J., Dixon D.R., Wilke A.E., Allen M.S., Bradstreet J.J. Randomized trial of hyperbaric oxygen therapy for children with autism. Res Autism Spectr Disord 2010, 4:268-275.
54. Tomchek S.D., Dunn W. Sensory processing in children with and without autism: a comparative study using the short sensory profile. Am J Occup Ther 2007, 61:190-200.
55. Roberts T.P., Schmidt G.L., Egeth M., et al. Electrophysiological signatures: magnetoencephalographic studies of the neural correlates of language impairment in autism spectrum disorders. Int J Psychophysiol 2008, 68:149-160.
56. Wilson T.W., Rojas D.C., Reite M.L., Teale P.D., Rogers S.J. Children and adolescents with autism exhibit reduced MEG steady-state gamma responses. Biol Psychiatry 2007, 62:192-197.
57. Farzin F., Rivera S.M., Hessl D. Brief report: visual processing of faces in individuals with fragile X syndrome: an eye tracking study. J Autism Dev Disord 2009, 39:946-952.
58. Aman M.G., Novotny S., Samango-Sprouse C., et al. Outcome measures for clinical drug trials in autism. CNS Spectrums 2004, 9:36-47.